Navigation Links
Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
Date:10/7/2008

LONDON, Oct. 7 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, announced today the results of the ongoing screening of its novel anti-inflammatory drugs using MD Biosciences' Immunoprofiler(TM) in vitro screening service. The screen was specifically chosen to identify and assess the anti-inflammatory properties of Morria's proprietary multi-functional anti-inflammatory compounds. The Immunoprofiler(TM) Screen uses rat macrophage cells which are stimulated using endotoxin (LPS), a potent inflammation-inducing agent. The assay measures key inflammatory mediators, which are released by the stimulated cells. A steroid comparator is included as a positive control.

Morria's lead compounds significantly reduced the levels of the following inflammatory mediators: GM-CSF (Granulocyte Macrophage Colony-Stimulating Factor), IL-1 beta, IL-6, TNF-alpha (Tumor Necrosis Factor alpha), MIP-1 alpha (Macrophage Inflammatory Protein 1 alpha), MCP-1 (Monocyte Chemoattractant Protein-1), IP-10 (Inducible Protein 10) and PGE-2 (Prostaglandin E-2). Cell proliferation assay (XTT reduction) demonstrated that these effects were not caused by cytotoxicity. The anti-inflammatory efficacy was comparable or better than the steroid control in each case.

"We are pleased by the wide range of divergent inflammatory mediators that we are modulating, several of which have been extensively covered in the scientific literature recently. Mediators, such as IL-6, IL-8 and TNF-alpha, are currently targets of research and development in the pharmaceutical field, and our synthetic compounds clearly modulate them efficiently," said Yuval Cohen, President of Morria Biopharmaceuticals.

Specifically, several of the inflammatory mediators assayed have been identified as important players in Morria's current clinical programs (allergic rhinitis and dermatitis) and pre-clinical programs (asthma, Inflammatory bowel disease [IBD], ophthalmology and cystic fibrosis) and also offer insights into potentially new pharmaceutical applications.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known, but previously elusive anti-inflammatory drug target. At the same time, they also protect cells and tissues against inflammatory damage. Morria is determined to become a pivotal player in the $20 billion anti-inflammatory drug market by developing and commercializing novel drugs for acute pulmonary and gastro-intestinal inflammatory diseases. For more information, please visit http://www.morria.com .

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order -- Persons in the business of disseminating information.

Contacts:

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer, Investors

cheer@rlcinc.com

Timothy Rathschmidt, Media

trathschmidt@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
2. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
3. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
4. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
8. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
9. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN DIEGO , Feb. 12, 2016 Biocom, ... life science community, took a group of San ... as part of its 2016 Precision Medicine Advocacy Fly-In. ... at the Food and Drug Administration (FDA), the Centers for ... (NIH), as well as San Diego U.S. Representatives Susan ...
(Date:2/11/2016)... , February 11, 2016 Non-profit Consortium ... Genetic Understanding to Support Research and Discovery ... today announced an ambitious plan to sequence 100,000 individuals. It ... countries and at least 7 of North and East Asian ... the first phase, the project will focus on creating phased ...
(Date:2/11/2016)... 2016  Spectra BioPharma Selling Solutions (Spectra) is ... biopharma companies the experience, expertise, operational delivery and ... sales teams. Created in concert with industry leading ... strategic and tactical needs of its clients by ... both personal and non-personal promotion. ...
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... to SEK 517.6 M (loss: 30.0). Earnings per share increased ... was SEK 537.4 M (neg: 74.7). , ... Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions announces ... Department in Missouri solved two ... reader (LPR) data from Vigilant Solutions. Brian ... in which the victim was walking out of a convenience store and witnessed ... next to his vehicle, striking his vehicle and leaving ...
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
Breaking Biology News(10 mins):